What Remidio Innovative Solutions does

Remidio Innovative Solutions is a Bangalore-headquartered healthtech company founded around 2009-2010 that designs and manufactures portable, AI-enabled ophthalmic diagnostic devices and associated software for vision care. Its product portfolio spans two hardware lines - the Insta series (handheld fundus cameras, portable slit lamps, autorefractometers, pachymeters, and a backpack-format InstaEyeClinic kit for outreach screening) and the Pristine series (multimodal clinic-based systems including widefield fundus, optical biometry, and comprehensive eye assessment devices) - together with the MediosHI AI platform that runs offline computer-vision algorithms for detecting diabetic retinopathy, glaucoma, age-related macular degeneration, and retinopathy of prematurity, plus the Remidio Connect cloud telemedicine platform for image management and referrals.

The company's core technology is a combination of smartphone- and optics-based portable retinal imaging with proprietary on-the-edge AI that operates without internet connectivity, enabling deployment in resource-limited and outreach settings. Remidio holds CDSCO, FDA 510(k), CE-MDR, and HSA Singapore approvals for its AI software, and claims the distinction of having India's first CDSCO-approved ophthalmic AI. Its Oculomics platform extends the retinal imaging base into non-invasive screening for systemic conditions including cardiovascular, kidney, liver, and neurological disease, with an active maternal-health program (pre-eclampsia) funded by the Bill & Melinda Gates Foundation.

Remidio monetizes through hardware sales (portable and clinic-based diagnostic devices), recurring AI/SaaS revenue from the MediosHI algorithms and Remidio Connect platform, and enterprise/government contracts for population-scale screening programs. It sells via direct enterprise sales, channel partners (e.g., Intelligent Retinal Imaging Systems in the US), and flagship government deployments in Kerala (Nayanamritham 2.0) and Karnataka (KIDROP). The company operates from Bangalore, Glen Allen (Virginia), and Singapore, with a reported 200+ employees, 4,000+ devices deployed, and 16M+ patients screened across 55+ countries. Sun Pharmaceutical acquired a 27.39% strategic stake in February 2023 for approximately $18 million.

Name

Remidio Innovative Solutions

Legal name

Remidio Innovative Solutions Private Limited

Website

https://remidio.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Remidio is a Bangalore-based healthtech company that develops portable, AI-powered ophthalmic diagnostic devices and offline AI algorithms for screening diabetic retinopathy, glaucoma, AMD, and ROP, serving hospitals, diabetologists, government screening programs, and outreach clinics across 55+ countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids) (HLAHAJAN)

akta.pro secondary industries

Ophthalmology & Vision Telemedicine Platforms (HLALAGAL), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)

Keywords

• Portable ophthalmic devices
• AI eye diagnostics
• Retinal imaging systems
• Diabetic retinopathy screening
• Ophthalmic telemedicine

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Hardware Devices: Sale of portable ophthalmic diagnostic devices including handheld fundus cameras, portable slit lamps, autorefractometers, and comprehensive diagnostic systems. Devices are sold to healthcare organizations, hospitals, clinics, and government health programs.
2. AI Software/SaaS: AI-powered diagnostic software integrated into devices and cloud platform. Medios HI AI algorithms for disease detection. Remidio Connect telemedicine platform for image management and clinician workflows.
3. Enterprise/Government Contracts: Large-scale screening program deployments with government health departments and public health programs. Partnerships with state governments for AI-powered eye screening initiatives.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Core offering

Remidio designs, develops, manufactures, and sells portable, AI-enabled ophthalmic diagnostic hardware (Insta handheld fundus cameras, slit lamps, autorefractometers, pachymeters, and Pristine multimodal clinical devices) integrated with on-the-edge AI screening software (MediosHI DR, Glaucoma, AMD, and ROP AI) and a cloud-based telemedicine platform (Remidio Connect). The portfolio enables point-of-care screening for diabetic retinopathy, glaucoma, AMD, and retinopathy of prematurity across hospitals, clinics, diabetologists, government screening programs, and outreach settings in 55+ countries.

Product overview

Remidio Innovative Solutions offers a comprehensive portfolio of portable, AI-powered ophthalmic diagnostic devices and telemedicine platforms. The product ecosystem consists of the Insta series (portable handheld devices including fundus camera, slit lamp, autorefractometer, pachymeter, and comprehensive screening kits) and the Pristine series (automated, multimodal diagnostic devices for clinical settings). The AI & Telemedicine Platform includes MediosHI AI algorithms (DR AI, Glaucoma AI, AMD AI, ROP AI) that process retinal images using on-the-edge (offline) AI technology, with MediosHI AI 3-in-1 combining multiple screening capabilities. Remidio Connect serves as the cloud-based platform connecting all devices and enabling telemedicine workflows. The company pioneered India's first CDSCO and FDA-approved offline AI algorithms for diabetic retinopathy, glaucoma, and AMD screening, with over 4,000 devices deployed worldwide and 16 million+ patients screened across 55+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Insta FOP NM 10 - Handheld Fundus Camera Portable, battery-operated handheld fundus camera for retinal imaging. Non-mydriatic (no pupil dilation required), captures high-quality wide-field retinal images using smartphone-based technology. Enables DR, glaucoma, and AMD screening at point of care.
• Insta PSL D20 - Portable Slit Lamp Portable digital slit lamp providing crystal-clear stills and video of the anterior eye segment. Features adjustable slit width and angle with multiple illumination modes. Used for cataract and eye infection screening.
• InstaRef R20 - Portable Autorefractometer Handheld autorefractometer using Shack-Hartmann wavefront technology. Delivers objective refraction in seconds with auto-alignment and auto-capture, enabling operation by non-specialists for accurate refractive error measurement.
• InstaEyeClinic Kit Comprehensive portable eye screening kit combining multiple handheld devices in a backpack format. Includes fundus camera, slit lamp, autorefractometer, and tonometer for complete anterior and posterior segment screening in under 10 minutes. Designed for outreach camps, home visits, and mobile clinics.
• Insta PM1 - Pachymeter Handheld pachymeter for corneal thickness measurement. Part of the portable diagnostic toolkit for comprehensive eye examinations.
• InstaZ - Automated Small Pupil Fundus Camera Next-generation automated fundus camera with offline AI capability. Designed for small pupil imaging without dilation, featuring automated capture for high-volume in-clinic use.
• Pristine 5.0 - Widefield Fundus Camera Advanced wide-field retinal imaging device designed for clinical efficiency. Provides high-quality retinal imaging with fast, efficient workflows for specialist offices and hospitals.
• Pristine VX 650 - Comprehensive Multimodal Eye Assessment System Automated, multimodal diagnostic device combining multiple imaging capabilities in one system. Designed to improve clinical efficiency through simple, high-throughput workflows.
• Pristine OBM 12 - Optical Biometer Optical biometer built for myopia clinics. Features automatic capture for accurate pediatric measurements, supporting myopia management and axial length assessment.
• Neubo 130 - ROP AI Enabled Ultra Widefield Pediatric Fundus Camera Ultra-widefield pediatric fundus camera with integrated ROP AI for neonatal retinal imaging. Designed specifically for screening premature infants in NICUs for Retinopathy of Prematurity.
• Remidio Connect Secure, cloud-based telemedicine platform connecting retinal imaging devices, AI outputs, clinicians, and health systems. Centralizes image management, review, reporting, and referrals for population-scale screening across distributed care settings. Supports multi-site deployments with longitudinal patient tracking. ISO-27001 certified, interoperable with EMR and PACS systems.
• MediosHI DR AI AI algorithm for automatically detecting referable diabetic retinopathy in retinal images. India's first CDSCO-approved offline AI for DR screening, works with portable retinal cameras for point-of-care diagnosis.
• MediosHI Glaucoma AI AI algorithm for glaucoma risk detection from fundus images. CDSCO-approved for early detection of glaucoma, addressing India's approximately 12 million glaucoma patients with 90% undiagnosed rate.
• MediosHI AMD AI AI algorithm for age-related macular degeneration detection from retinal images. CDSCO-approved for screening AMD, addressing the growing burden of macular degeneration in aging populations.
• MediosHI ROP AI World's first truly offline AI solution for screening and clinical documentation of Retinopathy of Prematurity. Enables consistent, objective analysis of retinal images in NICUs for early identification of at-risk preterm infants. Demonstrated sensitivity of ~96% and specificity of ~98%.
• MediosHI AI 3 in 1 Combined AI screening platform that simultaneously screens for diabetic retinopathy, glaucoma, and AMD from a single retinal image. Integrates three AI algorithms into one solution for comprehensive eye disease detection.
• Remidio Anterior Imaging Module (AIM) Smartphone-based slit lamp imaging module for seamless documentation, secure data capture, and easy integration with existing digital records and tele-consultation workflows.
• Remidio Microscopic Recording Device (MRD) Surgical documentation and live streaming device for microscope recording. Enables recording of surgical procedures for training, documentation, and consultation purposes.

Quantifiable outcome

• Screened over 16 million people across 55+ countries
• +4 more outcomes

Named customers11 records

Segments8 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability11 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core, strategic and flagship.

• Ratan Tata Innovation HubcoreStrategic or Co-development Partner · 1 November 2025Association with Ratan Tata Innovation Hub and A.P. Innovation Society for the MedTech Innovation Challenge, receiving 297 applications from researchers and innovators.
• RetinaRiskstrategicTechnology or Integration · 1 April 2025Partnership to strengthen AI-driven diabetic retinopathy screening in India and Iceland. Combines Remidio's AI-powered retinal screening with RetinaRisk's risk-based model for diabetic retinopathy management.
• Kerala Government (Nayanamritham 2.0)flagshipStrategic or Co-development Partner · 1 February 2025World's first AI-powered government screening program for chronic eye diseases. Government-backed initiative screening for diabetic retinopathy, glaucoma, and age-related macular degeneration using Remidio's AI-powered solutions.
• Karnataka Government (KIDROP)flagshipStrategic or Co-development PartnerPublic-private partnership with Karnataka government to prevent infant blindness through ROP screening. Program is expanding nationwide to address rising premature births in India.
• Aravind Eye HospitalcoreStrategic or Co-development PartnerStrategic partnership with Aravind Eye Hospital for deployment of Remidio's diagnostic solutions. Dr. R. Venkatesh, CMO of Aravind Eye Hospital, serves as advisor to Remidio.
• L.V. Prasad Eye InstitutecoreStrategic or Co-development PartnerPartnership with LVPEI, a leading eye care institution in India, for deployment of AI-powered diagnostic solutions.
• Intelligent Retinal Imaging Systems (IRIS)coreChannel Partner/ Reseller/ DistributorUS-based partnership where IRIS distributes and implements Remidio's solutions. IRIS CEO Steve Martin noted the partnership has had powerful impact on healthcare providers seeking to close care gaps and create better outcomes for patients with diabetes.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Eyenuk: Eyenuk develops EyeArt, an FDA-cleared AI system for autonomous diabetic retinopathy screening. It is the most direct competitor to Remidio's MediosHI DR AI in the US and global markets, serving similar primary care and endocrinology channels with a software-only model.
• Digital Diagnostics: Digital Diagnostics (formerly IDx-DR) developed the first FDA-authorized autonomous AI for diabetic retinopathy detection (IDx-DR). It competes directly with Remidio's MediosHI DR AI in the US primary care and retail clinic segments.
• AEYE Health: AEYE Health provides FDA-cleared AI for autonomous DR screening using portable retinal imaging, with a similar product positioning to Remidio's MediosHI platform targeting primary care and non-ophthalmologist settings.
• Intelligent Retinal Imaging Systems (IRIS): IRIS is a US-based retinal screening service that partners with Remidio for device distribution and is also a direct competitor providing AI-enabled DR screening in primary care settings across the United States. The relationship demonstrates overlap between partner and competitor dynamics in this market.

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic diagnostic devices (OCT, fundus cameras, slit lamps) with deep hospital channel penetration. As a broad incumbent it competes with Remidio's Pristine series in hospital/clinic settings while Remidio targets portable, AI-enabled primary care segments where Zeiss is less established.
• Topcon Healthcare: Topcon is a major incumbent in retinal imaging, refraction, and AI screening (including its Harmony and Maestro systems with Imagenet/AI integration). It competes with Remidio in optometry and ophthalmology channels globally and could leverage its scale to enter portable AI screening segments.
• Heidelberg Engineering: Heidelberg Engineering is a leader in OCT and confocal retinal imaging (Spectralis) widely used by ophthalmologists. It is a broad incumbent in retinal diagnostic imaging that could extend into AI-enabled, portable screening segments currently dominated by Remidio.
• Nidek Co., Ltd. Nidek is a Japanese ophthalmic equipment manufacturer offering fundus cameras, autorefractometers, and optical biometers. It competes with Remidio's InstaRef and Pristine product lines in refraction and retinal imaging, particularly in Asian and emerging markets.
• Optos (Nikon): Optos, part of Nikon, is a leader in ultra-widefield retinal imaging (Daytona, California) used in retinal specialty practices. It is a broad incumbent in retinal imaging that competes with Remidio's Pristine widefield and Neubo pediatric fundus systems in hospital and specialty channels.

Emerging players

• Phelcom Technologies: Phelcom is a Brazilian startup developing portable, smartphone-based fundus cameras (Eyer) with AI integration for DR and other retinal disease screening. It is an emerging player in the same portable, AI-enabled retinal imaging niche as Remidio, focused on Latin America.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/remidioconnect
• YouTubeyoutube.com/channel/UC34951Y5YnHeUlk1_0PTRNw
• Facebookfacebook.com/timeline
• LinkedInlinkedin.com/company/remidio-innovative-solutions-pvt-ltd-
• Instagraminstagram.com/remidioconnect

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remidio Innovative Solutions